Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice

Journal of Molecular and Cellular Cardiology

Volumn 121, Issue , 2018, Pages 124-133

  Bonnard, Benjamin ^a   Pieronne Deperrois, Marie ^b   Djerada, Zoubir ^b   Elmoghrabi, Soumaya ^a   Kolkhof, Peter ^c   Ouvrard Pascaud, Antoine ^b   Mulder, Paul ^b   Jaisser, Frédéric ^a   Messaoudi, Smail ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c BAYER AG   (Germany)

Author keywords

Cardio renal syndrome; Diastolic dysfunction; Finerenone; Mineralocorticoid receptor

Indexed keywords

CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; FINERENONE; MINERALOCORTICOID RECEPTOR; PHOSPHOLAMBAN; EPLERENONE; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG MECHANISM; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; HEART PROTECTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; COMPLICATION; DIASTOLIC HEART FAILURE; DISEASE MODEL; DRUG EFFECT; GENETICS; HEMODYNAMICS; HUMAN; PATHOPHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; EPLERENONE; HEART FAILURE, DIASTOLIC; HEMODYNAMICS; HUMANS; MICE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC;

EID: 85049758919     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2018.06.008     Document Type: Article

References (57)

1. Roth, G.A. et al., Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 132 (2015), 1667–1678.
2. Bui, A.L., Horwich, T.B., Fonarow, G.C., Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8 (2011), 30–41.
3. Azad, N., Lemay, G., Management of chronic heart failure in the older population. J. Geriatr. Cardiol. JGC 11 (2014), 329–337.
4. Mann, J.F., Gerstein, H.C., Pogue, J., Bosch, J., Yusuf, S., Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134 (2001), 629–636.
5. Hillege, H.L. et al., Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 (2000), 203–210.
6. Forman, D.E. et al., Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 43 (2004), 61–67.
7. Sarnak, M.J., Cardiovascular complications in chronic kidney disease. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 41 (2003), 11–17.
8. Abdo, A.S., Basu, A., Geraci, S.A., Managing chronic heart failure patient in chronic kidney disease. Am. J. Med. 124 (2011), 26–28.
9. Pitt, B. et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341 (1999), 709–717.
10. Pitt, B. et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003), 1309–1321.
11. Zannad, F. et al., Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364 (2011), 11–21.
12. Jaisser, F., Farman, N., Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol. Rev. 68 (2016), 49–75.
13. Bärfacker, L. et al., Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7 (2012), 1385–1403.
14. Pitt, B. et al., Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34 (2013), 2453–2463.
15. Vinhas, M., Araújo, A.C., Ribeiro, S., Rosário, L.B., Belo, J.A., Transthoracic echocardiography reference values in juvenile and adult 129/Sv mice. Cardiovasc. Ultrasound, 11(12), 2013.
16. Domínguez, E. et al., Non-invasive in vivo measurement of cardiac output in C57BL/6 mice using high frequency transthoracic ultrasound: evaluation of gender and body weight effects. Int. J. Card. Imaging 30 (2014), 1237–1244.
17. Vandesompele, J. et al., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 3(7), 2002 research0034.1–0034.11.
18. Heydemann, A. et al., Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J. Clin. Invest. 119 (2009), 3703–3712.
19. Filippatos, G. et al., A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart J. 37 (2016), 2105–2114.
20. Park, M. et al., Associations between kidney function and subclinical cardiac abnormalities in CKD. J. Am. Soc. Nephrol. JASN 23 (2012), 1725–1734.
21. Farshid, A., Pathak, R., Shadbolt, B., Arnolda, L., Talaulikar, G., Diastolic function is a strong predictor of mortality in patients with chronic kidney disease. BMC Nephrol., 14(280), 2013.
22. Elkareh, J. et al., Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertens Dallas Tex 1979:49 (2007), 215–224.
23. Kennedy, D.J. et al., Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertens Dallas Tex 1979:47 (2006), 488–495.
24. Yuen, D.A. et al., Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel Antifibrotic mechanism. PLoS One, 5, 2010, e9543.
25. Kennedy, D.J. et al., Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am. J. Physiol.-Ren. Physiol. 294 (2008), F450–F454.
26. Winterberg, P.D., Jiang, R., Maxwell, J.T., Wang, B., Wagner, M.B., Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD). Phys. Rep., 4, 2016.
27. Siedlecki, A.M., Jin, X., Muslin, A.J., Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int. 75 (2009), 800–808.
28. Bro, S., Bollano, E., Brüel, A., Olgaard, K., Nielsen, L.B., Cardiac structure and function in a mouse model of uraemia without hypertension. Scand. J. Clin. Lab. Invest. 68 (2008), 660–666.
29. Bongartz, L.G. et al., Target organ cross talk in cardiorenal syndrome: animal models. Am. J. Physiol. Ren. Physiol. 303 (2012), F1253–F1263.
30. Agrawal, S. et al., Heart failure and chronic kidney disease: should we use spironolactone?. Am J Med Sci 350 (2015), 147–151.
31. Matsumoto, Y. et al., Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J. Am. Coll. Cardiol. 63 (2014), 528–536.
32. Edelmann, F. et al., Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309 (2013), 781–791.
33. Pitt, B. et al., Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370 (2014), 1383–1392.
34. Bristow, M.R. et al., Detection and Management of Geographic Disparities in the TOPCAT trial: Lessons Learned and Derivative Recommendations. JACC Basic Transl. Sci. 1 (2016), 180–189.
35. Patel, R.B., Shah, S.J., Fonarow, G.C., Butler, J., Vaduganathan, M., Designing future clinical trials in heart failure with preserved ejection fraction: lessons from TOPCAT. Curr. Heart Fail. Rep. 14 (2017), 217–222.
36. Aeschbacher, B.C. et al., Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am. J. Hypertens. 14 (2001), 106–113.
37. Di Bello, V. et al., Early left ventricular mechanics abnormalities in prehypertension: a two-dimensional strain echocardiography study. Am. J. Hypertens. 23 (2010), 405–412.
38. Dupont, S. et al., The onset of left ventricular diastolic dysfunction in SHR rats is not related to hypertrophy or hypertension. Am. J. Physiol. Heart Circ. Physiol. 302 (2012), H1524–H1532.
39. Di Lullo, L., Gorini, A., Russo, D., Santoboni, A., Ronco, C., Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 5 (2015), 254–266.
40. Feniman-De-Stefano, G.M.M. et al., Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther. Adv. Cardiovasc. Dis. 9 (2015), 158–167.
41. Lin, C., Zhang, Q., Zhang, H., Lin, A., Long-term effects of low-dose spironolactone on chronic Dialysis patients: a randomized placebo-controlled study. J. Clin. Hypertens. Greenwich Conn 18 (2016), 121–128.
42. Michea, L. et al., Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertens Dallas Tex 1979:52 (2008), 295–300.
43. Kass, D.A., Bronzwaer, J.G.F., Paulus, W.J., What mechanisms underlie diastolic dysfunction in heart failure?. Circ. Res. 94 (2004), 1533–1542.
44. Amann, K., Tyralla, K., Cardiovascular changes in chronic renal failure–pathogenesis and therapy. Clin. Nephrol. 58:Suppl. 1 (2002), S62–S72.
45. Iraqi, W. et al., Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) study. Circulation 119 (2009), 2471–2479.
46. Riser, B.L. et al., Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy. Am. J. Pathol. 184 (2014), 2908–2921.
47. Liu, H.-F. et al., CCN3 suppresses TGF-β1-induced extracellular matrix accumulation in human mesangial cells in vitro. Acta Pharmacol. Sin. 39 (2018), 222–229.
48. Asp, M.L., Martindale, J.J., Heinis, F.I., Wang, W., Metzger, J.M., Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies. Biochim. Biophys. Acta BBA - Mol. Cell Res. 1833 (2013), 895–900.
49. Hajjar, R.J., Kang, J.X., Gwathmey, J.K., Rosenzweig, A., Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 95 (1997), 423–429.
50. Hajjar, R.J., Schmidt, U., Kang, J.X., Matsui, T., Rosenzweig, A., Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum ca(2+)-ATPase. Circ. Res. 81 (1997), 145–153.
51. Kennedy, D. et al., Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J. Am. Soc. Nephrol. JASN 14 (2003), 90–97.
52. Mattiazzi, A., Kranias, E.G., The role of CaMKII regulation of phospholamban activity in heart disease. Front. Pharmacol., 5, 2014.
53. Tanaka, K. et al., Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. Circ. Heart Fail. 7 (2014), 976–985.
54. Takimoto, E. et al., Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase a phosphorylation sites. Circ. Res. 94 (2004), 496–504.
55. Borlaug, B.A., Kass, D.A., Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc. Med. 16 (2006), 273–279.
56. James, P.A. et al., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
57. Sandesara, P.B. et al., Diastolic blood pressure and adverse outcomes in the TOPCAT (treatment of preserved cardiac function heart failure with an aldosterone antagonist) trial. J. Am. Heart Assoc., 7, 2018.